Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  vinorelbine tartrate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 202 for your search:
Start Over
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML18527, NCT00121836
Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571BDE28, 2005-001537-15, NCT00372476
Phase III Randomized Study of Epirubicin/Vinorelbine vs Epirubicin Alone for Advanced Breast Cancer (Summary Last Modified 06/1999)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor:
Protocol IDs: DAN-DBCG-94-03, EU-95008
Phase III Randomized Study of TAX/CBDCA vs VNB/CDDP for Stage IV and Selected Stage IIIB non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-9509
Phase III Randomized Study of High-Dose vs Low-Dose Docetaxel vs Standard Chemotherapy with Vinorelbine or Ifosfamide for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy (Summary Last Modified 08/97)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-95088, RP-56976-TAX-320, NCI-V96-0830
Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000065002, FRE-IALT, EU-96010, NCT00002823
Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02725, ID99-303, U10CA045809, CDR0000067853, MDA-ID-99303, NCCAM, NCI-T99-0046, RTOG-0270, NCT00005838
Phase III Randomized Study of Cisplatin and Vinorelbine With or Without Bexarotene in Patients With Chemotherapy-Naive Advanced or Metastatic Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069-49
Phase III Comparison of Vinorelbine vs 5-FU/CF in Patients with Inoperable, Previously Untreated Stage IV non-Small Cell Lung Cancer (Summary Last Modified 06/91)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: BW-P70-34972-02, NCI-V91-0069
Phase III Comparison of Melphalan vs Vinorelbine in Women with Anthracycline-Resistant Breast Cancer (Summary Last Modified 05/91)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: BW-P70-34972-01, NCI-V91-0068
Phase III Randomized Study of VNB/DOX vs DOX Alone in Metastatic or Recurrent Breast Cancer (Summary Last Modified 08/95)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor:
Protocol IDs: CAN-NCIC-MA8, NCI-V92-0010, MA8
Phase III Randomized Study of CDDP vs CDDP/VNB for Previously Untreated Stage IV and Selected Stage IIIB Nonsmall Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: over 18
Sponsor: NCI
Protocol IDs: SWOG-9308
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: GOG-0204, NCT00064077
Phase III Randomized Study of Vinorelbine With or Without Trastuzumab (Herceptin®) in Women With HER2-Positive Progressive Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0347, S0347, NCT00103233
Start Over